• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Hum Lact . The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination

tetano

Editor, Senior Moderator
J Hum Lact


. 2021 Jun 27;8903344211027112.
doi: 10.1177/08903344211027112. Online ahead of print.
The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination


Hannah G Juncker[SUP] 1 2 [/SUP], Sien J Mulleners[SUP] 1 [/SUP], Marit J van Gils[SUP] 3 [/SUP], Christianne J M de Groot[SUP] 4 [/SUP], Dasja Pajkrt[SUP] 1 [/SUP], Aniko Korosi[SUP] 2 [/SUP], Johannes B van Goudoever[SUP] 1 [/SUP], Britt J van Keulen[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being administered around the world; however, lactating women were excluded from SARS-CoV-2 vaccine trials. Therefore, knowledge about the effect of vaccination in this specific group is limited. This information is essential to empower lactating women to make a well-informed decision on their choice for vaccination. After natural infection, SARS-CoV-2 specific antibodies are present in human milk, which might offer protection for her newborn. The dynamics of these antibodies in human milk following vaccination remain to be elucidated.
Research aim: To determine the effect of vaccination with BNT162b2 on the levels of SARS-CoV-2 specific IgA in human milk.
Methods: In this prospective longitudinal study, we included lactating women who received the BNT162b2 vaccine. Human milk samples were collected prior to vaccination and 3, 5, 7, 9, 11, 13, and 15 days after both vaccine doses. Samples were analyzed using enzyme-linked immunosorbent assay against the spike protein of SARS-CoV-2.
Results: In total, 366 human milk samples from 26 lactating women were analyzed. A biphasic response was observed, with SARS-CoV-2 specific immunoglobulin A (IgA) starting to increase between day 5 and 7 after the first dose of the vaccine. After the second dose, an accelerated IgA antibody response was observed.
Conclusion: After vaccination with the mRNA-based BNT162b2 vaccine, a SARS-CoV-2 specific antibody response was observed in human milk. The presence of SARS-CoV-2 specific IgA after vaccination is important as antibodies are transferred via human milk, and thereby might provide protection to infants against COVID-19.

Keywords: BNT162b2; COVID-19; Pfizer; breastfeeding; coronavirus; immunization; immunoglobulins; lactation; secretory IgA.
 
Back
Top Bottom